AbbVie (ABBV) Presented New Lung Cancer Clinical Data At WCLC 2026

AbbVie (NYSE: ABBV) unveiled new clinical data at the 2026 World Conference on Lung Cancer that covers several lung cancer programs across its pipeline. Key updates included efficacy and safety readouts for investigational therapies ABBV-1480, telisotuzumab adizutecan, and ABBV-706 in non small cell and small cell lung cancer. The company outlined an expanded set of ongoing lung cancer trials that it stated could reshape its future oncology portfolio and longer term growth profile. For...